Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $6.21B.
ENTERPRISE VALUE (EV)
$6.21B
Ligand Pharmaceuticals Incorporated
Market Cap
$5.94B
Enterprise Value (EV)
$6.21B
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | $5.94B | $6.21B |
| GRAIL Inc. (GRAL)vs › | $6.00B | $6.03B |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.82B | $5.75B |
| CG Oncology Inc. (CGON)vs › | $5.70B | $5.69B |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.63B | $5.47B |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | $5.39B |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.40B | $9.06B |
| Doximity, Inc. (DOCS)vs › | $5.36B | $5.09B |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | $6.56B |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.60B | $7.53B |
Market Cap
$5.94B
Total Debt
$446.19M
Cash
$174.93M
Enterprise Value
$6.21B
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
